Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
F 11.70 -2.90% -0.35
DVAX closed down 2.9 percent on Monday, March 18, 2024, on 1.17 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup -2.90%
Volume Surge Other -2.90%
NR7 Range Contraction -2.90%
NR7-2 Range Contraction -2.90%
Lower Bollinger Band Walk Weakness -2.90%
Lower Bollinger Band Touch Weakness -2.90%

   Recent Intraday Alerts

Alert Time
Down 3% about 18 hours ago
Down 1 ATR about 18 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Down 2 % about 18 hours ago
Fell Below Lower Bollinger Band about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dynavax Technologies Corporation Description

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Inflammatory Diseases Hepatitis B Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Autoimmune And Inflammatory Disease Novel Products Tlr7 Tlr9

Is DVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.15
52 Week Low 9.485
Average Volume 2,044,025
200-Day Moving Average 13.60
50-Day Moving Average 13.07
20-Day Moving Average 12.60
10-Day Moving Average 12.48
Average True Range 0.36
RSI (14) 31.03
ADX 22.26
+DI 13.67
-DI 33.40
Chandelier Exit (Long, 3 ATRs) 12.18
Chandelier Exit (Short, 3 ATRs) 12.73
Upper Bollinger Bands 13.36
Lower Bollinger Band 11.84
Percent B (%b) -0.09
BandWidth 12.12
MACD Line -0.25
MACD Signal Line -0.17
MACD Histogram -0.0813
Fundamentals Value
Market Cap 1.51 Billion
Num Shares 129 Million
EPS 0.41
Price-to-Earnings (P/E) Ratio 28.54
Price-to-Sales 4.63
Price-to-Book 2.76
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.25
Resistance 3 (R3) 12.29 12.15 12.16
Resistance 2 (R2) 12.15 12.01 12.13 12.13
Resistance 1 (R1) 11.93 11.93 11.86 11.88 12.10
Pivot Point 11.79 11.79 11.75 11.77 11.79
Support 1 (S1) 11.56 11.65 11.49 11.52 11.30
Support 2 (S2) 11.42 11.56 11.40 11.27
Support 3 (S3) 11.20 11.42 11.24
Support 4 (S4) 11.15